A new player has entered the competitive field of pharmaceutical innovation, as Perceptic, a startup spearheaded by a trio of former Palantir executives, officially emerged from stealth mode. The company announced a $12 million seed funding round, led by London-based Accel, with participation from Air Street Capital and Elder Gull. This infusion of capital is earmarked primarily for engineering expansion and growing Perceptic’s customer base, signaling an ambition beyond initial product validation.
Perceptic’s core offering is an end-to-end AI platform designed to streamline the complex journey of drug development, from initial discovery through to clinical trial design. This comprehensive approach differentiates it from many other AI-driven startups in the biopharmaceutical sector, which often focus on optimizing specific, isolated segments of the process. Tilman Flock, Perceptic’s cofounder and CEO, who spent nearly seven years at Palantir developing its commercial AI platform for life sciences, articulated this distinction, noting that previous efforts to improve the drug discovery process have typically been linear, leading to fragmented insights. Perceptic aims to serve as the “connective tissue,” integrating disparate AI tools with the proprietary and external data pharmaceutical companies rely upon.
The platform is engineered to be infrastructure and model agnostic, allowing pharmaceutical clients to integrate their own data, hardware, and AI models while Perceptic provides the unifying layer. This flexibility is critical in an industry where data provenance and traceability are paramount, particularly given the regulatory scrutiny and the financial stakes involved. Flock emphasized that the system is designed to avoid AI hallucinations, a common concern in AI applications where models can generate fictitious information. Perceptic’s architecture ensures that every claim can be traced directly back to its source, providing the necessary audit trail for rigorous scientific and regulatory review.
Perceptic targets three key areas within pharmaceutical research and development. First, it seeks to accelerate the scientific due diligence required for big pharma companies to assess and license external assets from biotechnology firms, potentially compressing weeks of work into mere hours. Second, the platform assists in selecting optimal indications for clinical trials, a strategic decision that can significantly impact investments totaling millions of dollars. Finally, Perceptic focuses on building robust data foundations for clinical trial design, claiming impressive results, such as a 50-fold increase in clinical data extractions.
The company’s software is already in use by several major pharmaceutical companies, though only Australian biotechnology firm CSL has been publicly named. Sonali De Rycker, the Accel partner who spearheaded the investment, highlighted the platform’s ability to “follow the drug” throughout its entire development lifecycle, rather than being confined to specific departmental silos within a large organization. De Rycker, who had been tracking Flock and his co-founders, Martin Copes and Zaki Trache, since their time as key engineers on Palantir’s AIP, noted that Perceptic had moved beyond pilot programs into paid production deployments before the investment was finalized.
The Perceptic team, currently numbering around 20 employees, draws heavily on talent from its founders’ Palantir background, particularly for its engineering operations based in London. This geographic concentration aligns with Europe’s rich talent pool in pharmaceuticals, particularly in Switzerland and the UK. While much of the engineering is rooted in Europe, the company’s customer base extends to the United States, indicating a planned expansion of its presence there. Nathan Benaich, founder and general partner of Air Street Capital, articulated a broader vision for the industry, suggesting that the next significant leap in pharma R&D will not come from isolated point solutions or advanced models alone, but from an overarching operating system that seamlessly connects data, decisions, and context across the multi-year development process. Perceptic aims to be that operating system, moving beyond the concept of product-market fit to focus on scaling its proven solution.
